<DOC>
	<DOCNO>NCT01769183</DOCNO>
	<brief_summary>The purpose study determine efficacy use topical Squalamine Lactate Ophthalmic Solution , 0.2 % treatment retinal neovascularization result proliferative diabetic retinopathy .</brief_summary>
	<brief_title>Squalamine Treatment Proliferative Diabetic Retinopathy</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Retinal Neovascularization</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Squalamine</mesh_term>
	<criteria>Age &gt; = 18 year Individuals &lt; 18 year old include PDR rare age group diagnosis PDR may questionable . Diagnosis diabetes mellitus ( type 1 type 2 ) Any one following consider sufficient evidence diabetes present : Current regular use insulin treatment diabetes Current regular use oral antihyperglycemia agent treatment diabetes Documented diabetes ADA and/or WHO criterion ( see Procedures Manual definition ) At least one eye meet study eye criterion Able willing provide inform consent Significant renal disease , define history chronic renal failure require dialysis kidney transplant . A condition , opinion investigator , would preclude participation study ( e.g. , unstable medical status include blood pressure , cardiovascular disease , glycemic control ) . Individuals poor glycemic control , within last 4 month , initiate intensive insulin treatment ( pump multiple daily injection ) plan next 4 month enrol . Participation investigational trial within 30 day randomization involve treatment drug receive regulatory approval indication study . Note : study participant receive another investigational drug participate study . Known allergy component study drug . Blood pressure &gt; 180/110 ( systolic 180 diastolic 110 ) . If blood pressure bring 180/110 antihypertensive treatment , individual become eligible . Myocardial infarction , acute cardiac event require hospitalization , stroke , transient ischemic attack , treatment acute congestive heart failure within 4 month prior randomization . Systemic antiVEGF proVEGF treatment within 4 month prior randomization . These drug use study . For woman childbearing potential : pregnant lactate intend become pregnant within next 3 year . Women potential study participant question potential pregnancy . Investigator judgment use determine pregnancy test need . Individual expect move area clinical center study . History allergy Squalamine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Proliferative Diabetic Retinopathy</keyword>
</DOC>